Today, Glenmark Pharmaceuticals has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients who are suffering from mild to moderate Coronavirus. On Friday, the Mumbai based drug firm had received manufacturing and marketing approval from the Drugs Controller General of India. The company said in a statement that FabiFlu is the first oral Favipiravir approved medication for the treatment of Coronavirus.
Glenn Saldanha, the Glenmark Pharmaceuticals Chairman and Managing Director said, “This approval comes at a time when cases in our country India are spiraling like never before, putting pressure on the healthcare system.”
Glenmark Pharmaceuticals company is hoping that the availability of an effective treatment such as Favipiravir will help assuage this pressure, and offer the patients in India a much needed and timely therapy option. Favipiravir is orally administered. It serves as a more convenient treatment option over other intravenously administered medications.
The drug Favipiravir will be available as a prescription-based medication for Rs 103/tablet, with recommended dose being 1,800 mg twice on day one, followed by 800 mg twice daily up to day 14. The drug has shown clinical improvement of up to 88 percent in mild to moderate Coronavirus cases.
On Saturday, India saw another record spike of 14,516 new COVID-19/ Coronavirus cases in a single day, pushing the tally to 3,95,048.
from TOPSTORIES – Tollywood https://ift.tt/2V5NjqW
0 Comments